Grifols, S.A.
https://www.grifols.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Grifols, S.A.
Pfizer Backs EU Manufacturing With €2.4bn Investment
Pfizer is betting big on its manufacturing plans in Europe, investing €1.2bn at respective sites in Ireland and Belgium to prepare for a number of launches it has lined up in the short term.
Rigel Ready To Hit The Ground Running After Early AML Drug Approval
Rezlidhia, which was only recently licensed by Rigal from Novo Nordisk-owned Forma Therapeutics, should challenge the market dominance of Servier's Tibsovo in the IDH-1 inhibitor subset of acute myeloid leukemia patients.
Genfit Pivots To Opposite End Of The Liver Disease Spectrum
Genfit CEO Pascal Prigent talks to Scrip about the company's high-profile trial failure in NASH and the pipeline pivot to various other drug candidates for rare liver diseases.
Finance Watch: Venture Capital Dominates Biopharma Funding So Far In 2022
Private Company Edition: Biomedtracker found that 53% of financings during the first quarter were venture capital deals versus 32% in Q1 of last year. Also, Qiming closed a $260m fund, Transition Bio raised a $50m series A round, ProfoundBio completed a $70m series A+ and MycoMedica raised $60m.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Diagnostic Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
-
- Alpha Therapeutic Corporation
- Biotest AG
- Goetech LLC
- GigaGen, Inc.
- Grifols Therapeutics, Inc.
- MedKeeper
- Talecris Biotherapeutics Inc.
- Haema AG.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice